↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

15 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Acitretin  1件: Acitretin;   D02754   4件: RARA, RXRA, RXRB, RXRG   1件: Th17 cell differentiation   1件:
37
 2   Adalimumab  51件: Adalimumab; Adalimumab injection [humira]; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Double-blind adalimumab; Etanercept or adalimumab; Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Open-label adalimumab; Open-labeladalimumabrescue; Sb5 (proposed biosimilar to adalimumab); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Fitc-adalimumab; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Ol adalimumab 40 mg; Start adalimumab in monotherapy; Treatment with adalimumab; Adalimumab 40 mg sc every other week; Adalimumab, etanercept, golimumab or infliximab; Gp2017 (adalimumab biosimilar);   D02597   1件: TNF   9件: Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 3   Alefacept  1件: Alefacept;   D02800   1件: CD58   1件: Cell adhesion molecules (CAMs)   6件:
37,
60,
65,
164,
284,
285
 4   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Kineret® (anakinra); Response to anakinra associated with methotrexate; Anakinra / kineret; Kineret® or anakinra;   D02934   2件: IL1R1, IL1R2   2件: Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 5   Brodalumab  1件: Brodalumab;   D10061   1件: IL17RA   2件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway   2件:
37,
51
 6   Calcitriol  4件: Calcitriol; Delayed release 6mp or calcitriol vs. purinethol; Rapamycin-calcitriol combination; Calcitriol & calcium;   D00129   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   8件:
37,
46,
49,
66,
96,
158,
235,
326
 7   Certolizumab pegol  11件: Certolizumab pegol; 99mtc-s-hynic certolizumab pegol; Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol (cdp870); Certolizumab pegol (rinn); Certolizumab pegol 400 mg; Infliximab, adalimumab, certolizumab pegol; Cimzia certolizumab pegol 200 mg/ml solution for injection;   D03441   1件: TNF   10件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway, Toll-like receptor signaling pathway   6件:
37,
46,
96,
97,
226,
271
 8   Efalizumab  1件: Efalizumab;   D03959   1件: ITGAL   2件: Cell adhesion molecules (CAMs), Natural killer cell mediated cytotoxicity   9件:
11,
13,
37,
46,
49,
53,
61,
95,
96
 9   Guselkumab  4件: Guselkumab; Guselkumab 100 mg; Guselkumab dose 1; Guselkumab dose 2;   D10438   1件: IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   3件:
37,
96,
97
 10   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 11   Ixekizumab  1件: Ixekizumab;   D10071   1件: IL17A   2件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway   4件:
37,
162,
269,
271
 12   Phosphorus P-32  0件:   -   -   -   1件:
37
 13   Risankizumab  4件: Risankizumab; Risankizumab iv; Risankizumab sc; Risankizumab (genetical recombination);   D11052   1件: IL23A   3件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation   4件:
37,
96,
97,
271
 14   Secukinumab  12件: Secukinumab; Secukinumab 150mg; Secukinumab 300mg; Secukinumab 300 mg, s.c.; Secukinumab (ain457); 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Ain457/secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab 150 milligram [cosentyx];   D09967   1件: IL17A   2件: Cytokine-cytokine receptor interaction, Rheumatoid arthritis   7件:
13,
37,
41,
46,
160,
269,
271
 15   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271